| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.004 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.004 |